Clinical Trial Update: A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Ifinatamab Deruxtecan in patients with pretreatment advanced or metastatic Esophageal Squamous Cell Carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Ifinatamab Deruxtecan (Ifinatamab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Esophageal Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING